Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.

NCT05330871 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

410

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: 1 Nebulized inhalation for booster groups
BIOLOGICAL: 2 Nebulized inhalation for booster groups
BIOLOGICAL: 3 Nebulized inhalation for booster groups
BIOLOGICAL: 4 Nebulized inhalation for booster groups
BIOLOGICAL: 5 Intramuscular injection for booster groups
BIOLOGICAL: 6 Intramuscular injection for booster groups
BIOLOGICAL: 7 Intramuscular injection for booster groups
BIOLOGICAL: 8 Intramuscular injection for booster groups
BIOLOGICAL: 9 Intramuscular injection for booster groups
BIOLOGICAL: 10 Intramuscular injection for booster groups
BIOLOGICAL: 11 Nebulized inhalation for booster groups
BIOLOGICAL: 12 Nebulized inhalation for booster groups
BIOLOGICAL: 13 Nebulized inhalation for booster groups
BIOLOGICAL: 14 Nebulized inhalation for booster groups
BIOLOGICAL: 15 Intramuscular injection for booster groups
BIOLOGICAL: 16 Intramuscular injection for booster groups
BIOLOGICAL: 17 Intramuscular injection for booster groups
BIOLOGICAL: 18 Intramuscular injection for booster groups
BIOLOGICAL: 19 Intramuscular injection for booster groups
BIOLOGICAL: 20 Intramuscular injection for booster groups

Sponsor

Seventh Medical Center of PLA General Hospital